SINOVAC BIOTECH LTD Annual Report - How They Did This Year

I’m breaking down Sinovac Biotech’s performance this past year into plain English. Instead of reading hundreds of pages of complex filings, you can use this guide to decide if the company fits your investment goals.

1. What does this company do?

Sinovac is a Beijing-based biopharmaceutical company that researches, manufactures, and sells human vaccines. Their portfolio includes vaccines for Hepatitis A and B, seasonal and pandemic flu, and enterovirus 71. They also developed the CoronaVac COVID-19 vaccine. Because their business relies on government health authorities purchasing products for national immunization programs, their success is driven by public health policy rather than traditional retail sales.

2. A Major "Red Flag" for Investors

Sinovac failed to file its 2024 annual report on time and is currently working to restore its standing with the SEC.

More importantly, the company disclosed that its financial reports for 2021, 2022, and 2023 were incorrect. They have "restated" these reports to correct previous accounting errors. The company advises that previous financial statements should no longer be relied upon. Investors should focus exclusively on the data provided in the most recent filings.

3. Recent Financial Moves (The "Dividend" Surprise)

In April 2025, Sinovac declared a special cash dividend of $55.00 per share.

While a large payout is notable, it is important to understand the context:

• Source of Funds: This dividend was not funded by current operating profits. Instead, the company utilized cash reserves held within its subsidiaries to make the payment.
• The "Catch": If you are involved in legal disputes regarding shares issued in a 2018 private placement, your dividend is held in an "escrow" account. These funds remain inaccessible until the courts resolve the ownership of those specific shares.

4. Major Risks

• Trust and Reliability: The need to restate three years of financial results indicates significant internal control failures, which complicates the process of verifying the company’s profit figures.
• The "Holding Company" Trap: Sinovac is incorporated in Antigua and Barbuda. You are investing in a holding company that controls Chinese manufacturing facilities through contracts rather than direct ownership. If Chinese regulations change, the government could restrict the company’s ability to move profits out of the country.
• Regulatory Pressure: As a foreign company, Sinovac is subject to the Holding Foreign Companies Accountable Act. If U.S. regulators are unable to inspect the company’s auditors, Sinovac faces the risk of being banned from trading on U.S. stock exchanges.

5. Future Outlook

Sinovac is currently focusing on the development of new vaccines, but its financial performance remains volatile. The company reported a profit in 2021 and 2024, but experienced losses in 2022 and 2023. These inconsistencies, paired with the recent accounting corrections and ongoing legal disputes, make long-term forecasting difficult.

Investment Takeaway: While the recent cash distribution provides some liquidity, the company’s history of accounting errors and unresolved legal battles suggests a high-risk environment. Investors should weigh the potential for future vaccine development against the significant uncertainty surrounding the company’s financial reporting and regulatory status.